logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Abbott India Ltd

Abbott India

Large Cap•3,659 Employees•IPO 1994
Current Price
₹26685.00
-515 (-1.89%)Updated
NSE :ABBOTINDIA
BSE :500488
Sector :Pharmaceuticals
Today's Range
26530
₹26685.00
indicator
27000
52 Week Range
52W Low₹26000.00
52W High₹37000.00
₹26685.00
indicator
Downside2.63%
Upside38.65%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹56,313.52 Cr
Market Cap
Total market value of company
P/E Ratio
37.32
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
15.52
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹710.12
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
18.98%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
46.20%
ROCE
Return on Capital Employed. >15% is good
Net Margin
22.47%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
18.71%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
11.74%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
11.60%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
11.50%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.05
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹1992.14
Book Value
Net asset value per share
Dividend Yield
1.79%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
75.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Robust profitability with ROE 35.7% and OPM 26.5%.
  • •Exceptional capital efficiency demonstrated by a 46.2% Return on Capital Employed.

Weaknesses

5 points
  • •High Price-to-Earnings (P/E) ratio of 43.40 suggests potential overvaluation.
  • •Elevated Price-to-Book value of 14.90 indicates a premium market valuation.

Opportunities

5 points
  • •Robust growth in the pharmaceutical and healthcare sector in India.
  • •Strong financial health supports strategic acquisitions or product diversification initiatives.

Threats

4 points
  • •Intense competition from domestic and international players in pharma sector.
  • •Adverse changes in government healthcare policies or drug pricing regulations.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹27886.67+₹1201.67+4.50%
R3₹27416.67+₹731.67+2.74%
R2₹27208.33+₹523.33+1.96%
R1₹26946.67+₹261.67+0.98%
PIVOT₹26738.3353.330.20%
CURRENT₹26685.00--
S1₹25536.67-₹1148.33-4.30%
S2₹26006.67-₹678.33-2.54%
S3₹26268.33-₹416.67-1.56%
S4₹26476.67-₹208.33-0.78%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.07L
(12 Mar 2026)
-22.9% vs avg
Delivery %
49.3%
(12 Mar 2026)
-7.6% vs avg
Avg Volume (20D)
0.09L
(12 Feb - 12 Mar)
20-day average
Avg Delivery %
56.9%
(12 Feb - 12 Mar)
Trend ↓
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %

Peer Comparison

Company Name
AJANTPHARM
Ajanta Pharma Ltd
ALKEM
Alkem Laboratories Ltd
AUROPHARMA
Aurobindo Pharma Ltd
DRREDDY
Dr Reddys Laboratories Ltd
GLAND
Gland Pharma Ltd
GLAXO
Glaxosmithkline Pharmaceuticals Ltd
GLENMARK
Glenmark Pharmaceuticals Ltd
IPCALAB
Ipca Laboratories Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
LAURUSLABS
Laurus Labs Ltd
LUPIN
Lupin Ltd
MANKIND
Mankind Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
ZYDUSLIFE
Zydus Lifesciences Ltd

About

ABBOTINDIA

Abbott India Ltd

Abbott India Limited is a prominent pharmaceutical company operating within India. Its business model centers on the research, development, manufacturing, and distribution of a wide range of pharmaceutical products catering to diverse therapeutic areas. The company's portfolio is extensive and addresses significant unmet medical needs across the Indian population.

A key aspect of Abbott India's business is its focus on specific therapeutic areas. These include gastroenterology, women's health, metabolic disorders, central nervous system conditions, and vaccines. The company also offers products for multispecialty needs, encompassing conditions such as insomnia, vitamin D deficiency, preterm labor, and pain management. This diversified approach allows Abbott India to serve a broad spectrum of patients and healthcare providers.

Further diversification is evident in Abbott India's product categories. The company manufactures and markets anti-infective agents, cardio-diabetological medications, hepatology products, hormone therapies, neuro-psychiatric medications, hepatic treatments, and products categorized as 'gennext' (likely referring to newer generation pharmaceuticals). A consumer care segment also forms part of their offerings, indicating a broader reach beyond purely prescription-based pharmaceuticals.

Abbott India's long history, dating back to 1910, speaks to its established presence and experience within the Indian pharmaceutical market. Headquartered in Mumbai, the company operates as a subsidiary of Abbott Capital India Limited, benefiting from the resources and expertise of its parent company. This structural positioning likely supports Abbott India's continued growth and market competitiveness.

In summary, Abbott India's business is characterized by its diversified pharmaceutical portfolio addressing major therapeutic areas and diverse patient needs. The company's long operational history, strategic focus, and parent company support contribute to its significant position within the Indian pharmaceutical landscape. Its range extends from prescription-based treatments to consumer healthcare products, allowing it to cater to a wide audience.

COMPANY FACTS - ABBOTINDIA

Registered Address

Godrej BKC, Plot C 68, G block, 16th Floor, Bandra Kurla Complex, Near MCA Club, Bandra ( E )

Mumbai

MAHARASHTRA

IN

Tel: 912250461000

Website:https://www.abbott.co.in/

Investor Relations:http://www.abbott.co.in/investor-relations/financials.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 3,659

IPO Date: 03/11/1994

MANAGEMENT - ABBOTINDIA

Mr. Munir Ahmed Shaikh

Non-Executive Chairman of the Board

Ms. Jyoti Saraph

Director - Finance

Ms. Sangeeta Shetty

Chief Compliance Officer, Company Secretary, Associate Director - Secretarial

Ms. Swati Dalal

Managing Director, Executive Director

Mr. Prithwish Banerji

Commercial Director - Womens Health, Metabolics and International Business

Mr. Rajan Kalantre

Director - Business Human Resources

Dr. Jejoe Karankumar

Director - Medical Affairs

Mr. Anuj Mehra

Commercial Director - NeuroLife, GenNext and Vaccines

Mrs. Namita Shah

Associate Director - New Product Introductions and Therapy Area Strategy

Ms. Richa Tripathi

Associate Director - Sales Force Effectiveness, Project Management Office

Ms. Alison Davies

Additional Non-Executive Director

Mr. Kaiyomarz Marfatia

Non-Executive Director

Investor Questions Answered

Abbott India Ltd (ABBOTINDIA) Stock FAQs

Get answers to the most common questions about Abbott India Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Abbott India Ltd (ABBOTINDIA) is ₹26,685. Today, the stock has declined by ₹515.00 (1.89%), trading in a range of ₹26,530 to ₹27,000. The stock opened at ₹27,000 with a trading volume of 6,590 shares.
Abbott India Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹56,313.52 crores, P/E ratio of 37.32, ROE of 18.98%, and ROCE of 46.20%. The dividend yield stands at 1.79%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Abbott India Ltd (ABBOTINDIA) is ₹37,000, while the 52-week low is ₹26,000. Currently trading at ₹26,685, the stock is 6.2% away from its 52-week low and 27.9% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Abbott India Ltd stock at ₹26,685 depends on multiple factors. The stock is currently trading with a P/E ratio of 37.32 and P/B ratio of N/A. Today's performance shows a loss of 1.89%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Abbott India Ltd offers a dividend yield of 1.79%, which means for every ₹100 invested at the current price of ₹26,685, you can expect to receive approximately ₹1.79 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Abbott India Ltd's key financial metrics include: P/E Ratio: 37.32, P/B Ratio: N/A, ROE: 18.98%, ROCE: 46.20%, Dividend Yield: 1.79%, EPS: ₹710.12, Book Value: ₹1,992.14, Debt-to-Equity: 0.05, and Current Ratio: N/A. The company's market cap stands at ₹56,313.52 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Abbott India Ltd stock opened at ₹27,000 and is currently trading at ₹26,685, showing a decline of ₹515.00 (1.89%). The intraday high is ₹27,000 and low is ₹26,530. The trading volume stands at 6,590 shares, indicating moderate market participation today.
Abbott India Ltd has a Price-to-Earnings (P/E) ratio of 37.32, which means investors are willing to pay ₹37.32 for every ₹1 of earnings. With an EPS of ₹710.12, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Abbott India Ltd has a market capitalization of ₹56,313.52 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹26,685) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Abbott India Ltd has a book value of ₹1,992.14 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹26,685, which is 1239.5% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Abbott India Ltd has a Return on Equity (ROE) of 18.98% and Return on Capital Employed (ROCE) of 46.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. Both metrics are strong, indicating efficient capital utilization. Higher percentages generally indicate better financial performance.
Abbott India Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Abbott India Ltd has a debt-to-equity ratio of 0.05, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Abbott India Ltd has an Earnings Per Share (EPS) of ₹710.12, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹26,685 and P/E ratio of 37.32, investors are paying 37.32 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Abbott India Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Abbott India Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Abbott India Ltd stock, consider: 1) Fundamental Analysis - Review P/E (37.32), ROE (18.98%), debt-to-equity (0.05), and growth rates. 2) Technical Analysis - Check 52-week range (₹26000.00 - ₹37000.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹26685.00) with book value (₹1992.14) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Abbott India Ltd share is ₹10.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹26,685 is 266750x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Abbott India Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹26000.00 - ₹37000.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.05 indicates leverage. 4) Liquidity Risk - Based on trading volume of 6,590 shares. 5) Valuation Risk - P/E of 37.32 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Abbott India Ltd operates in the industry with key metrics: P/E ratio of 37.32, ROE of 18.98%, market cap of ₹56,313.52 crores, and dividend yield of 1.79%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.05), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Abbott India Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹26,685, with a 52-week range of ₹26000.00 to ₹37000.00. Based on fundamentals like P/E (37.32), ROE (18.98%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Abbott India Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹26685.00. 2) Fundamental Deterioration - Declining ROE (currently 18.98%), increasing debt (D/E: 0.05), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Abbott India Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 1.79%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.